Iovance Biotherapeutics, based in San Carlos, California, specializes in cell therapies for cancer, focusing on its lead product, Amtagvi, for melanoma treatment. The company employs 557 people and went public in 2008.
Frederick G Vogt bought 25,000 shares of IOVA on 14 May at $1.69 per share, worth a total of $42K. They now own 374,646 IOVA shares, or a 7% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
